PMC7338642_01
PMC7338642_02
PMC7338642_03
Clinical manifestations of the case. *Plasma derived; **recombinant;  immune tolerance induction.
10.1177_2058738420934618-fig1.jpg
PMC7338642_03_10.1177_2058738420934618-fig1.jpg
fig1-2058738420934618
He finally used non-factor replacement (emicizumab) without inhibitor recurrence (Figure 1).